Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 13 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer

  • Yiqing Duan1
  • Dan Liu1
  • Qian Huang1
  • Jianghan Man1
  • Li Li1
  • Yuanbo Xue1
  1. 1Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan
Read full textPDFDOICite

Abstract

The median overall survival (OS) for patients with recurrent or metastatic cervical cancer after progression on first-line therapy is only 5–12 months. We retrospectively reviewed four patients who received modified induction–maintenance therapy. All of the patients achieved clinical benefit to varying degrees, with one attaining progression-free survival (PFS) of over 58 months and an OS of 86 months. However, these findings should be interpreted with caution and warrant validation in larger prospective studies.

Related

  1. Adrenal hormones in the maintenance of glucose homeostasis during prolonged fasting in male glucagon‐deficient mice
    Sayumi Kanie, Koki Nishida, Yusuke Seino +11
    Journal of diabetes investigationPeer-reviewedCC BY-NCFull textEndocrinology & metabolismEurope PMC
  2. The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials
    Chaudhry Zaid Riaz, Muhammad Raza, Iman Afraz +8
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Survival Outcomes of Post‐Induction Treatment Strategies in Patients With Partial Response Hypopharyngeal Squamous Cell Carcinoma: A Propensity Score‐Weighted Analysis
    Hui‐Ching Lau, Huiying Huang, Ji Li +6
    Cancer medicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Prolonged survival after small-cell transformation of EGFR-mutant lung adenocarcinoma: a case report
    Yaxin Yan, Dongjie Du, Fenghua Wen +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  5. Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Emeline Guiard, Florian Clatot, Caroline Even +5
    European Journal of CancerPeer-reviewedPublisher termsFull text20 citedGeneral biologyOncologyHAL

Cite

BibTeXRIS
BibTeX
@article{duan2026case,
  title = {{Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer}},
  author = {Yiqing Duan and Dan Liu and Qian Huang and Jianghan Man and Li Li and Yuanbo Xue},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1961384},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1961384/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer
AU  - Yiqing Duan
AU  - Dan Liu
AU  - Qian Huang
AU  - Jianghan Man
AU  - Li Li
AU  - Yuanbo Xue
PY  - 2026
DA  - 2026/10/19
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1961384
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1961384/full
AB  - The median overall survival (OS) for patients with recurrent or metastatic cervical cancer after progression on first-line therapy is only 5–12 months. We retrospectively reviewed four patients who received modified induction–maintenance therapy. All of the patients achieved clinical benefit to varying degrees, with one attaining progression-free survival (PFS) of over 58 months and an OS of 86 months. However, these findings should be interpreted with caution and warrant validation in larger prospective studies.
SN  - 2234-943X
ER  -